Skip Navigation

Nephrology Dialysis Transplantation 2005 20(Supplement 4):iv27-iv30; doi:10.1093/ndt/gfh1089
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aljama, P.
Right arrow Articles by Martin de Francisco, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aljama, P.
Right arrow Articles by Martin de Francisco, A. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Antibody-mediated pure red cell aplasia (PRCA): ensuring future progress by collecting data from a registry

Pedro Aljama1, Julia Carracedo1, Juan Antonio Madueño1, Rafael Ramirez1, Alejandro Martin-Malo1 and Angel L. Martin de Francisco2

1 Servicio de Nefrologia and Research Unit, Hospital Reina Sofia, Cordoba and 2 Servicio de Nefrologia, Hospital Marqués de Valencilla, Santander, Spain

Correspondence and offprint requests to: Pedro Aljama, MD, PhD, Hospital Reina Sofia de Cordoba, Servicio de Nefrologia and Research Unit, Avda. Menendez pidal, sn., 14004 Cordoba, Spain. Email: pedro.aljama.sspa{at}juntadeandalucia.es

The recent emergence of antibody (Ab)-mediated pure red cell aplasia (PRCA) resulting from administration of certain erythropoiesis-stimulating agents (ESAs) has heightened awareness of the potential for this disorder in patients receiving ESAs for anaemia associated with chronic kidney disease (CKD). The Spanish Society of Nephrology sponsored an independent registry for analysis of patients who developed epoetin-induced, Ab-mediated PRCA in Spain. Twelve patients from 11 regional hospitals were included in the Spanish PRCA registry from November 2000 to December 2002 that met the criteria for Ab-mediated PRCA. Patients were reported using a standardized form specifically developed for PRCA, and serum samples were analysed in a central laboratory at Reina Sofia University Hospital in Cordoba, Spain. The characteristics of these patients, their serological and haematological results, and the outcomes of immunosuppressive therapies are presented. The Spanish PRCA registry serves as a model for establishing an independent global PRCA registry sponsored by the various nephrology societies in European Union countries, and elsewhere and coordinated by key investigators from the respective countries.

Keywords: epoetin; PRCA; registry; Spanish cases; therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.